Imatinib, a specific tyrosine kinase inhibitor is a new anticancer agent, which has shown excellent efficacy in managing chronic myeloid leukemia. It is well tolerated with few side effects. Commonest adverse events are maculopapular eruptions and periorbital edema were reported. Severe adverse reactions are seen in 5% of patients. Exfoliative dermatitis has been very rarely reported with this drug. We report a case of a 55-year-old female who initially presented with a maculopapular rash and developed erythroderma on continuation of the drug.